The present invention provides MDM2 inhibitor compounds of Formula I, ##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

The present invention provides MDM2 inhibitor compounds of Formula I, ##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

The invention relates to an organic molecule having a structure of the formula I ##STR00001## where X=CN or CF.sub.3; D=chemical unit having a structure of the formula I-1: ##STR00002## where #=attachment point of the unit of formula I-1 to the central phenyl ring in the structure of formula I; A and B=independently of one another are selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z; and Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

The invention relates to an organic molecule having a structure of the formula I ##STR00001## where X=CN or CF.sub.3; D=chemical unit having a structure of the formula I-1: ##STR00002## where #=attachment point of the unit of formula I-1 to the central phenyl ring in the structure of formula I; A and B=independently of one another are selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z; and Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

An isoquinolinone compound acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1), and the use thereof, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be used to prepare a drug for preventing, treating or ameliorating inflammation and/or inflammation-related diseases, diabetes and/or diabetes-related diseases in patients, and especially can be used to prepare a drug for preventing, treating or ameliorating non-alcoholic fatty liver diseases in patients.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Telomerase reverse transcriptase (TERT) expression enhancing compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

Telomerase reverse transcriptase (TERT) expression enhancing compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.